Nexalin Technology’s (NXL) “Hold” Rating Reaffirmed at Maxim Group

Posted by Doug Wharley on Dec 5th, 2024

Nexalin Technology (NASDAQ:NXL – Get Free Report)‘s stock had its “hold” rating reiterated by equities researchers at Maxim Group in a research report issued to clients and investors on Thursday,Benzinga reports.

Nexalin Technology Trading Up 1.2 %

NASDAQ NXL traded up $0.05 during trading hours on Thursday, reaching $4.20. 614,726 shares of the company’s stock were exchanged, compared to its average volume of 1,421,484. The firm has a fifty day moving average of $2.45 and a 200-day moving average of $1.56. Nexalin Technology has a one year low of $0.25 and a one year high of $4.49. The stock has a market cap of $54.01 million, a PE ratio of -6.56 and a beta of 3.78.

Nexalin Technology (NASDAQ:NXL – Get Free Report) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.23) earnings per share (EPS) for the quarter. Nexalin Technology had a negative net margin of 3,407.98% and a negative return on equity of 187.59%. The business had revenue of $0.04 million during the quarter.

Hedge Funds Weigh In On Nexalin Technology

A hedge fund recently bought a new stake in Nexalin Technology stock. CVI Holdings LLC bought a new position in shares of Nexalin Technology, Inc. (NASDAQ:NXL – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 55,462 shares of the company’s stock, valued at approximately $94,000. CVI Holdings LLC owned 0.52% of Nexalin Technology as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 0.65% of the company’s stock.

About Nexalin Technology

(Get Free Report)

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.